Macdonald R L, McLean M J
Department of Neurology, University of Michigan, Ann Arbor 48104.
Electroencephalogr Clin Neurophysiol Suppl. 1987;39:200-8.
The actions of clinically used anticonvulsant drugs on sustained high frequency repetitive firing of action potentials and on responses to gamma aminobutyric acid (GABA) have been determined using mouse neurons in cell culture, and a classification of anticonvulsant drug actions has been developed based on these cellular actions. Actions of the anticonvulsant drugs were accepted as clinically relevant only if they occurred at concentrations achieved in cerebrospinal fluid or in plasma unbound to plasma proteins. Based on their cellular mechanisms of actions, drugs have been divided into 3 categories: (1) Phenytoin, carbamazepine and valproic acid limited sustained high frequency repetitive firing but did not alter GABA responses. (2) Phenobarbital and the benzodiazepines, clonazepam, diazepam and nitrazepam, augmented postsynaptic GABA responses. These drugs limited sustained high frequency repetitive firing only at concentrations above the therapeutic range in ambulatory patients, but equal to concentrations achieved in the acute treatment of status epilepticus. (3) Ethosuximide failed to reduce sustained high frequency repetitive firing or enhance GABA responses even at supertherapeutic concentrations. Limitation of sustained high frequency repetitive firing by anticonvulsant drugs correlated well with efficacy against generalized tonic-clonic seizures in man and against maximal electroshock seizures in experimental animals. Enhancement of postsynaptic GABA responses correlated with efficacy against generalized absence seizures in man and against pentylenetetrazol seizures in animals. Ethosuximide, however, did not alter GABA responses or sustained high frequency repetitive firing suggesting that its action against generalized absence seizures in man and pentylenetetrazol seizures in experimental animals occurs by an additional, as yet unknown, mechanism.
已利用细胞培养的小鼠神经元确定了临床使用的抗惊厥药物对动作电位持续高频重复发放以及对γ-氨基丁酸(GABA)反应的作用,并基于这些细胞水平的作用建立了抗惊厥药物作用的分类。只有当抗惊厥药物的作用发生在脑脊液或未与血浆蛋白结合的血浆中所达到的浓度时,才被认为具有临床相关性。根据其细胞作用机制,药物被分为3类:(1)苯妥英、卡马西平和丙戊酸可限制动作电位的持续高频重复发放,但不改变GABA反应。(2)苯巴比妥和苯二氮䓬类药物,如氯硝西泮、地西泮和硝西泮,增强突触后GABA反应。这些药物仅在门诊患者高于治疗范围但等同于癫痫持续状态急性治疗时所达到的浓度时,才会限制动作电位的持续高频重复发放。(3)乙琥胺即使在超治疗浓度下也不能减少动作电位的持续高频重复发放或增强GABA反应。抗惊厥药物对动作电位持续高频重复发放的限制与对人类全身强直阵挛性发作以及实验动物最大电休克发作的疗效密切相关。突触后GABA反应的增强与对人类全身失神发作以及动物戊四氮发作的疗效相关。然而,乙琥胺并未改变GABA反应或动作电位的持续高频重复发放,这表明其对人类全身失神发作和实验动物戊四氮发作的作用是通过一种额外的、尚不清楚的机制实现的。